Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04279769 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
A Phase 1 study, sponsored by Calithera Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04279769 is a Phase 1 study that has completed, run by Calithera Biosciences. The registered enrollment target is 32 participants.
The verdict
NCT04279769, a Phase 1 study, has completed, sponsored by Calithera Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase 1b multiple ascending dose escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.
Interventions
- DRUG Placebos
- DRUG CB-280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-07-03 |
| Est. Completion | 2021-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04279769
The ClinicalTrials.gov registry entry for NCT04279769 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04279769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04279769 about?
NCT04279769 is a clinical study titled "Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis". This is a phase 1b multiple ascending dose escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.
What is the current status of trial NCT04279769?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-07-03. Estimated completion is 2021-11-23.
What interventions are being tested in trial NCT04279769?
The interventions under investigation include: Placebos (DRUG), CB-280 (DRUG).
Who is sponsoring clinical trial NCT04279769?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.